Ignite Creation Date:
2024-05-06 @ 7:20 PM
Last Modification Date:
2024-10-26 @ 3:05 PM
Study NCT ID:
NCT05978401
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-08-07
First Post:
2023-07-26
Brief Title:
Safety Tolerability and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer
Sponsor:
Guangzhou Gloria Biosciences Co Ltd
Organization:
Guangzhou Gloria Biosciences Co Ltd
Study Overview
Official Title:
A Phase III Study Evaluating the Safety Tolerability and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer Triumph-02
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multicenter open Phase III study The trial consists of two parts Part1 is a dose-escalationexpansion study Part2 is a combination of GLS-010 and GLS-010GLS-012 with standard chemotherapy for advanced non-small-cell lung cancer respectively to assess preliminary efficacy at the combination dose
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None